CTLA4 and neoplasm: To further improve the anti-tumor ability, we need to select the appropriate patient population, explore the optimal radiotherapy regimens (dose, fractionation and volume), immunotherapy regimens (such as CTLA-4 inhibitors and PD-1/PD-L1 inhibitors), the sequence of radiotherapy and immunotherapy, and reduce the immunosuppressive effects and toxicity of radiotherapy.